IRIS
LAPUCCI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.048
Totale 3.048
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 3.048
Totale 3.048
Salva come PNG Salva come JPEG
Città #
Genova 1.276
Genoa 765
Vado Ligure 614
Rapallo 383
Bordighera 10
Totale 3.048
Salva come PNG Salva come JPEG
Nome #
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers 142
Osteopathic Manipulative Therapy and Multiple Sclerosis: A Proof-of-Concept Study 142
Different MRI patterns in MS worsening after stopping fingolimod 140
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 120
Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of “black holes” 111
"Limbic encephalitis with acute onset and Hu antibodies treated with rituximab: Paraneoplastic or non-paraneoplastic disorder?" 110
How much do periventricular lesions assist in distinguishing migraine with aura from CIS? 107
Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis? 106
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 104
Effects of aging on finger movements in multiple sclerosis 99
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies 94
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 91
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 83
Two-way crossed cerebellar diaschisis in a clinically isolated syndrome suggestive of multiple sclerosis 82
Neuroimaging Findings in Mild Cognitive Impairment 75
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 74
A longitudinal clinical and MRI evaluation of the treatment with erenumab 73
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population 69
Assessing upper limb function in Multiple Sclerosis by an engineered glove 67
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 62
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 55
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study 53
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 51
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 50
Clinical and radiological correlates of apathy in multiple sclerosis 47
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 47
Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic 47
In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis 46
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 46
ADVANCED SUSCEPTIBILITY AND DIFFUSION WEIGHTED IMAGING IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS: FROM RESEARCH TO CLINICAL APPLICATIONS 46
Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis 42
null 41
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 41
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis 41
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 39
A real-world study of alemtuzumab in a cohort of Italian patients 38
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities 37
Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature 37
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 35
Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study 33
The role of disconnection in explaining disability in multiple sclerosis 30
Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma 27
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 25
Improved detection of multiple sclerosis lesions with T2-prepared double inversion recovery at 3T 25
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia 24
Sex differences in neuroimaging biomarkers in healthy subjects and dementia 23
The effect of Cladribine and Fingolimod treatments on retinal atrophy 22
Mapping tissue microstructure across the human brain on a clinical scanner with soma and neurite density image metrics 21
Vaccinations in patients with multiple sclerosis: a real-world, single-center experience 21
null 20
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 16
Effect of SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with disease modifying therapies 16
Brain lesion microstructure in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein disease 14
A real-world study of Alemtuzumab in a cohort of Italian patients 13
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient 13
Multiparametric Characterization and Spatial Distribution of Different MS Lesion Phenotypes 12
Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection 9
Lesion phenotyping based on magnetic susceptibility in pediatric multiple sclerosis 9
Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis 9
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 8
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series 7
E200k familial creutzfeldt-jakob disease presenting with subacute multiple cranial neuropathy 7
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis 5
Totale 3.199
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.779
article - articoli 14.986
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 564
Totale 31.329
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020331 0 0 0 0 0 0 77 61 63 68 50 12
2020/2021344 25 18 36 62 49 32 13 22 22 38 15 12
2021/2022339 21 4 12 28 21 30 12 72 27 43 19 50
2022/2023480 43 50 10 47 50 68 7 29 66 14 74 22
2023/2024626 24 42 18 76 35 83 122 37 30 18 36 105
2024/2025729 105 113 72 90 196 153 0 0 0 0 0 0
Totale 3.199